ORMP
- Oramed Pharmaceuticals Inc.
()
Overview
Company Summary
Oramed Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development of oral drug delivery systems. The company has pioneered a unique technology that enables the oral delivery of proteins, peptides, and other medicines that are typically administered through injections.
Traditionally, many therapeutic drugs, particularly those involving proteins and peptides, have required injection as the primary administration method. Injecting medications can be inconvenient, painful, and may cause patient discomfort. Oramed is focused on revolutionizing drug delivery by providing an oral alternative to injection.
The company's flagship product is an oral insulin capsule called ORMD-0801. Oramed has successfully completed clinical trials for this innovative medication, which is designed to help individuals with diabetes manage their condition through a simpler, more convenient, and less invasive approach. By allowing insulin to be taken orally rather than through injection, ORMD-0801 has the potential to improve diabetic patients' quality of life and treatment adherence.
In addition to oral insulin, Oramed is also engaged in developing oral delivery solutions for other drugs, such as GLP-1 analogs, leptin, and various vaccines. Their technology has the potential to revolutionize the way many medications are administered, benefiting patients and healthcare professionals alike.
Overall, Oramed Pharmaceuticals Inc. is focused on advancing the field of oral drug delivery and enhancing patient care by providing effective, convenient, and non-invasive alternatives to traditional injection-based therapies.